Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines

Vaccine

Volumn 30, Issue 24, 2012, Pages 3710-3716

  Ladhani, Shamez N ^a   Flood, Jessica S ^a   Ramsay, Mary E ^a   Campbell, Helen ^a   Gray, Stephen J ^a   Kaczmarski, Edward B ^a   Mallard, Richard H ^a   Guiver, Malcolm ^a   Newbold, Lynne S ^a   Borrow, Ray ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Adolescents; Capsular group B; Capsular group Y; Epidemiology; Infants; Invasive meningococcal disease; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT DISEASE; ADULT; ADULT DISEASE; AGED; ARTICLE; CHILD; FATALITY; HUMAN; INCIDENCE; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; MOLECULAR TYPING; MORTALITY; NEISSERIA MENINGITIDIS; SEROTYPING; WALES; YOUNG ADULT;

EID: 84860998698     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.011     Document Type: Article

References (33)

1. Visintin C., Mugglestone M.A., Fields E.J., Jacklin P., Murphy M.S., Pollard A.J. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ 2010, 340:c3209.
2. Pollard A.J., Nadel S., Ninis N., Faust S.N., Levin M. Emergency management of meningococcal disease: eight years on. Arch Dis Child 2007, 92:283-286.
3. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362:1511-1520.
4. Gray S.J., Trotter C.L., Ramsay M.E., Guiver M., Fox A.J., Borrow R., et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006, 55:887-896.
5. Campbell H., Andrews N., Borrow R., Trotter C., Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17:840-847.
6. Gasparini R., Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011, 7:170-182.
7. Racloz V.N., Luiz S.J. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010, 10:175.
8. Reacher M.H., Shah A., Livermore D.M., Wale M.C., Graham C., Johnson A.P., et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000, 320:213-216.
9. Levy C., Taha M.K., Weil O.C., Quinet B., Lecuyer A., Alonso J.M., et al. Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr Infect Dis J 2010, 29:618-623.
10. Hershey J.H., Hitchcock W. Epidemiology and meningococcal serogroup distribution in the United States. Clin Pediatr (Phila) 2010, 49:519-524.
11. Yogev R., Tan T. Meningococcal disease: the advances and challenges of meningococcal disease prevention. Hum Vaccin 2011, 7:828-837.
12. Department of Health Annual HPV vaccine coverage in England in 2009/2010. Gateway Reference 15439; 2011.
13. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
14. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
15. Maiden M.C., Spratt B.G. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999, 354:615-616.
16. Feil E.J., Maiden M.C., Achtman M., Spratt B.G. The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol Biol Evol 1999, 16:1496-1502.
17. Siddique A., Buisine N., Chalmers R. The transposon-like Correia elements encode numerous strong promoters and provide a potential new mechanism for phase variation in the meningococcus. PLoS Genet 2011, 7:e1001277.
18. Swartley J.S., Marfin A.A., Edupuganti S., Liu L.J., Cieslak P., Perkins B., et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997, 94:271-276.
19. Beddek A.J., Li M.S., Kroll J.S., Jordan T.W., Martin D.R. Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun 2009, 77:2989-2994.
20. Trotter C.L., Ramsay M.E., Gray S., Fox A., Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006, 6:616-617.
21. Maiden M.C., Ibarz-Pavon A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
22. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
23. Trotter C.L., Edmunds W.J. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002, 324:809.
24. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
25. Caugant D.A., Maiden M.C. Meningococcal carriage and disease - population biology and evolution. Vaccine 2009, 27(Suppl. 2):B64-B70.
26. Thulin Hedberg S., Toros B., Fredlund H., Olcen P., Molling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011, 16(23). pii=19885.
27. Ines-Agudelo C., Sanabria O.M., Ovalle M.V. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008, 14:990-991.
28. Ladhani S.N., Lucidarme J., Newbold L.S., Gray S.J., Carr A.D., Findlow J., et al. Invasive meningococcal capsular group Y disease, England and wales, 2007-2009. Emerg Infect Dis 2012, 18:63-70.
29. Centers for Disease Control and Prevention. Activebacterial core surveillance (ABCs) report. Emerging infections program network. Neisseria meningitidis; 2009 [October 2010 File - 17 November 2010].
30. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2005, 54:1-21.
31. Le Saux N., Bettinger J.A., Wootton S., Halperin S.A., Vaudry W., Scheifele D.W., et al. Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. Can J Infect Dis Med Microbiol 2009, 20:e130-e134.
32. Wilder-Smith A., Chow A., Goh K.T. Emergence and disappearance of W135 meningococcal disease. Epidemiol Infect 2010, 138:976-978.
33. Fransen F., Hamstra H.J., Boog C.J., van Putten J.P., van den Dobbelsteen G.P., van der Ley P. The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease. Infect Immun 2010, 78:3177-3186.